NCT04109976 - A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis | Biotech Hunter

Enrollment

214

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

November 5, 2020

Study Completion Date

November 13, 2020

Conditions

Psoriatic Arthritis

Interventions

DRUG

Bimekizumab

Study participants will receive bimekizumab at pre-specified time points.

Trial Locations (47)

11201

Dv0004 50010, Brooklyn

16635

Dv0004 50020, Duncansville

19610

Dv0004 50006, Wyomissing

20902

Dv0004 50026, Wheaton

21742

Dv0004 50015, Hagerstown

25801

Dv0004 50050, Beckley

28144

Dv0004 50031, Salisbury

28210

Dv0004 50125, Charlotte

38305

Dv0004 50001, Jackson

40504

Dv0004 50028, Lexington

45417

Dv0004 50040, Dayton

48910

Dv0004 50019, Lansing

63141

Dv0004 50016, St Louis

70836

Dv0004 50023, Baton Rouge

75150

Dv0004 50036, Mesquite

76710

Dv0004 50009, Waco

83702

Dv0004 50024, Boise

87102

Dv0004 50029, Albuquerque

07728

Dv0004 50005, Freehold

02919

Dv0004 50008, Johnston

Unknown

Dv0004 40061, Brno

Dv0004 40009, Pardubice

Dv0004 40063, Prague

Dv0004 40066, Prague

Dv0004 40010, Uherské Hradiště

Dv0004 40012, Zlín

Dv0004 40029, Hamburg

Dv0004 40079, Szentes

Dv0004 40038, Elblag

Dv0004 40088, Elblag

Dv0004 40096, Gdynia

Dv0004 40042, Krakow

Dv0004 40092, Krakow

Dv0004 40037, Lublin

Dv0004 40091, Nowa Sól

Dv0004 40044, Poznan

Dv0004 40118, Torun

Dv0004 40041, Warsaw

Dv0004 40097, Warsaw

Dv0004 40098, Warsaw

Dv0004 40039, Wroclaw

Dv0004 40043, Wroclaw

Dv0004 20005, Moscow

Dv0004 20013, Petrozavodsk

Dv0004 20004, Saint Petersburg

Dv0004 20014, Ulyanovsk

Dv0004 20015, Yaroslavl

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY